Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as an Elite provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.

Mohit Khera, M.D., M.B.A., M.P.H., Associate Professor, is the Director of the Laboratory for Andrology Research at McNair Medical Institute, Baylor College of Medicine. He is also the Medical Director of the Executive Health Program at Baylor. Dr. Khera is a Board-certified urologist specializing in male infertility, male and female sexual dysfunction, and declining testosterone levels in aging men. Dr. Khera's research focuses on the efficacy of botulinum toxin type A in treating Peyronie's disease as well as genetic and epigenetic studies on post-finasteride syndrome patients and testosterone replacement therapy. Dr. Khera is rated as an Elite provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Hypogonadism, Peyronie Disease, Erectile Dysfunction (ED), Hormone Replacement Therapy (HRT), and Prostatectomy.

Larry I. Lipshultz, M.D., is Professor of Urology and Chief of the Scott Department of Urology’s Division of Male Reproductive Medicine and Surgery. Dr. Lipshultz, who holds the Smith Chair in Reproductive Medicine, is a well-known authority on abnormalities of male reproduction, erectile dysfunction, and male hormone production. He received his medical training at the University of Pennsylvania and received fellowship training at the University of Texas at Houston as the first AUA research scholar. Recognized as a leading expert on men’s health, Dr. Lipshultz is a highly respected author and editor, as well as lecturer. Teacher as well as physician, researcher, writer, and editor, Dr. Lipshultz instituted a fellowship training program in male reproductive medicine and surgery that has trained more than 80 physicians who are now in practice both here and abroad. Dr. Lipshultz is rated as an Elite provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Peyronie Disease, Hypogonadism, Infertility, Vasectomy, and Hormone Replacement Therapy (HRT).